Literature DB >> 30355535

Substance use disorders and PTSD: Examining substance use, PTSD symptoms, and dropout following imaginal exposure.

Amber M Jarnecke1, Nicholas P Allan2, Christal L Badour3, Julianne C Flanagan4, Therese K Killeen4, Sudie E Back5.   

Abstract

Integrated exposure-based interventions to treat substance use disorders (SUD) and posttraumatic stress disorder (PTSD) may not be widely utilized, in part, because of clinician concerns that such interventions will worsen symptomatology and lead to treatment dropout. In order to address this question, the current pilot study examined whether participants' ratings of craving and distress following imaginal exposure predicted increased substance use, PTSD severity, and treatment dropout. Participants (N = 46) were U.S. military Veterans who met criteria for current SUD and PTSD. Subjective ratings of craving and distress, and past-week substance use and PTSD symptom severity were assessed at each treatment session. Multilevel modeling tested whether lagged ratings of craving and distress predicted the following week's frequency of substance use and PTSD severity. Discrete time survival analysis, using proportional odds Cox ratio, examined whether craving and distress ratings predicted treatment dropout. The findings revealed that neither craving nor distress following imaginal exposure were associated with the following week's substance use or PTSD severity. However, participants with higher craving and distress were more likely to drop out before completing treatment. Future research is needed to develop strategies to increase treatment retention for individuals at-risk for treatment dropout and identify mechanisms that account for the association between in-session ratings of craving and distress and dropout.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Addiction; Imaginal exposure; Posttraumatic stress disorder; Substance use; Treatment retention

Mesh:

Year:  2018        PMID: 30355535      PMCID: PMC6324999          DOI: 10.1016/j.addbeh.2018.10.020

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  28 in total

Review 1.  Concurrent Treatment of Substance Use and PTSD.

Authors:  Julianne C Flanagan; Kristina J Korte; Therese K Killeen; Sudie E Back
Journal:  Curr Psychiatry Rep       Date:  2016-08       Impact factor: 5.285

2.  A Randomized Controlled Trial Comparing Integrated Cognitive Behavioral Therapy Versus Individual Addiction Counseling for Co-occurring Substance Use and Posttraumatic Stress Disorders.

Authors:  Mark P McGovern; Chantal Lambert-Harris; Arthur I Alterman; Haiyi Xie; Andrea Meier
Journal:  J Dual Diagn       Date:  2011-01-01

3.  A survey of PTSD screening and referral practices in VA addiction treatment programs.

Authors:  Helena E Young; Craig S Rosen; John W Finney
Journal:  J Subst Abuse Treat       Date:  2005-06

4.  The use of alcohol and drugs to self-medicate symptoms of posttraumatic stress disorder.

Authors:  Murdoch Leeies; Jina Pagura; Jitender Sareen; James M Bolton
Journal:  Depress Anxiety       Date:  2010-08       Impact factor: 6.505

5.  Craving and physiological reactivity to trauma and alcohol cues in posttraumatic stress disorder and alcohol dependence.

Authors:  Scott F Coffey; Julie A Schumacher; Paul R Stasiewicz; Amber M Henslee; Lauren E Baillie; Noah Landy
Journal:  Exp Clin Psychopharmacol       Date:  2010-08       Impact factor: 3.157

6.  Substance use comorbidity among veterans with posttraumatic stress disorder and other psychiatric illness.

Authors:  Ismene L Petrakis; Robert Rosenheck; Rani Desai
Journal:  Am J Addict       Date:  2011-03-17

7.  Predictors of dropout in concurrent treatment of posttraumatic stress disorder and alcohol dependence: Rate of improvement matters.

Authors:  Laurie J Zandberg; David Rosenfield; Elizabeth Alpert; Carmen P McLean; Edna B Foa
Journal:  Behav Res Ther       Date:  2016-03-03

8.  Symptom exacerbations in trauma-focused treatments: Associations with treatment outcome and non-completion.

Authors:  Sadie E Larsen; Shannon Wiltsey Stirman; Brian N Smith; Patricia A Resick
Journal:  Behav Res Ther       Date:  2015-12-18

9.  Characteristics of U.S. veterans who begin and complete prolonged exposure and cognitive processing therapy for PTSD.

Authors:  Juliette M Mott; Sasha Mondragon; Natalie E Hundt; Melissa Beason-Smith; Rebecca H Grady; Ellen J Teng
Journal:  J Trauma Stress       Date:  2014-06

10.  Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDA's Clinical Trials Network.

Authors:  Denise A Hien; Huiping Jiang; Aimee N C Campbell; Mei-Chen Hu; Gloria M Miele; Lisa R Cohen; Gregory S Brigham; Carrie Capstick; Agatha Kulaga; James Robinson; Lourdes Suarez-Morales; Edward V Nunes
Journal:  Am J Psychiatry       Date:  2009-11-16       Impact factor: 18.112

View more
  4 in total

1.  Does trauma-focused exposure therapy exacerbate symptoms among patients with comorbid PTSD and substance use disorders?

Authors:  Cynthia L Lancaster; Daniel F Gros; Michael C Mullarkey; Christal L Badour; Therese K Killeen; Kathleen T Brady; Sudie E Back
Journal:  Behav Cogn Psychother       Date:  2019-04-23

2.  Does exposure exacerbate symptoms in veterans with PTSD and alcohol use disorder?

Authors:  Jessica C Tripp; Moira Haller; Ryan S Trim; Elizabeth Straus; Craig J Bryan; Brittany C Davis; Robert Lyons; Jessica L Hamblen; Sonya B Norman
Journal:  Psychol Trauma       Date:  2020-07-16

3.  Seeing the forest for the trees: Predicting attendance in trials for co-occurring PTSD and substance use disorders with a machine learning approach.

Authors:  Teresa López-Castro; Yihong Zhao; Skye Fitzpatrick; Lesia M Ruglass; Denise A Hien
Journal:  J Consult Clin Psychol       Date:  2021-10

4.  Mothering, Substance Use Disorders and Intergenerational Trauma Transmission: An Attachment-Based Perspective.

Authors:  Florien Meulewaeter; Sarah S W De Pauw; Wouter Vanderplasschen
Journal:  Front Psychiatry       Date:  2019-10-18       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.